



COST is supported by the EU Framework Programme Horizon 2020



European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome COST Action - CA15111

Management Committee meeting, Work Group No 2 and No 4 meeting

Agenda 14 February 2019 Europe Royale Hotel Bucharest 60 Strada Franceză, Bucharest, Romania

13 February 2019			
- 19.00	Arrival of participants		
20.00 - 22.00	Dinner		
14 February 2019			
	Welcome & Organization		
09.00 - 9.30	Carmen Adella Sirbu, Local Meeting Chair		
	Modra Murovska, CA15111 Chair		
	Management Committee meeting		
09.30 - 11.00	1. Modra Murovska, Current GP3 situation - implemented measures and planned measures.		
2. Fernando Estévez-López, Slobodan Sekulic, Activities of WG1 after London meeting (what is don			
	 Carmen Scheibenbogen, Enrica Capelli, Activities of WG2 after London meeting (what is done, results). Derek Pheby, Activities of WG3 after London meeting (what is done, results). 		
	5. Elin Bole Strand, Jerome Authier, Activities of WG4 after London meeting (what is done, results).		
	6. Carmen Adella Sirbu, current situation with STSM. How to increase activity of ECIs in participating countries.		
	7. Lorenzo Lorusso, Evelina Shikova, Interaction with the Cost Academy on dissemination (what is done, how to increase dissemination activity).		
11.00 - 11.20	Coffee break		
	8. Lorenzo Lorusso, Anne Marit Mengshoel, Webpage, information and involvement of SMS and patients		

11.20 - 13.00	 organizations. 9. All MC members, International conferences/congresses, local activities (activities in the participating countries) planned during GP3. 10. Other issues (prepared and submitted projects, next MC meeting etc.) 11. Clarification of the WGs plan for the next GP4 period 		
13.00 - 14.00	Lunch		
$\begin{array}{c} 14:00-15:40\\ 16:00-17:00 \end{array}$	Work Group No 2 meeting	Work Group No 4 meeting	
	 Leader Carmen Scheibenbogen, Enrica Capelli Update Biomarker Studies Update new biomarker and multiparameter studies (metabolic, autoantibodies) Ongoing multiparameter study Biomarkers to subgroup ME/CFS Preparation of document with recommendations for biomarker usage and development of biomarker Enrica Capelli, Summary on autoantibodies. Francisco Westermeier, Presentation about endothelial function in ME/CFS focused on potential biomarkers. 	 Leader Jeromie Authier, Luis Nacul Jeromie Authier Presentation of achieved results corresponding to the GP3 work plan. Anne-Marit Mengshoels' presentation Effects of non- pharmacological interventions and patients'experiences of participating in such interventions. Luis Nacul, Report of Protocol for ME/CFS diagnostic (Includes recommendation for research purposes) Jose Alegre/Olli Polo, Report on Symptom management and relief for ME/CFS (pharmacological) Giorgos Sakkas /Ruud Vermulen, Report on draft for European Landscape on Diagnosis of ME/CFS for publication by Jerome Authier/Jean Dominique, Report on a draft of Neuropsychological review procedures on ME/CFS Discussion on next steps for: 6.1.Alignment of contents with outputs from Working Groups 1 (Epidemiology); 2 (Biomarkers); and 3 (Socio- Economics), Production of first final draft of document with recommendations from WGs, Planning inputs from the patient community and Charities, Planning Dissemination. 	
15.40 - 16.00	Coffee break		
17:00 – 18:00	WG 2 and WG4 joint meeting Discuss on the subgrouping of patients based on biomar autonomic testing and handgrip.	kers including routine lab, neurologic and functional studies of	